Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial.
Nai-Jung Chiang
No relevant relationships to disclose
Chiun Hsu
No relevant relationships to disclose
Jen-Shi Chen
No relevant relationships to disclose
Hiso-Hui Tsou
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Yang-Shen Shan
No relevant relationships to disclose
Shiu-Feng Huang
No relevant relationships to disclose
Chang-Fang Chiu
No relevant relationships to disclose
Kuan-Der Lee
No relevant relationships to disclose
Li-Tzong Chen
No relevant relationships to disclose